Stockhouse.com uses cookies on this site. By continuing to use our service, you agree to our use of cookies. Cookies are used to offer you a better browsing experience and to analyze our traffic. We also use them to share usage information with our partners. See full details.
I Agree
×
Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Privacy Policy | Disclaimer

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Privacy Policy | Disclaimer
Please Try Again {{ error }}

Send my password

Return to Login
SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

Bullboard - Stock Discussion Forum Isotechnika Pharma Inc IPHAF

Healthcare Biotechnology

GREY:IPHAF - Post Discussion

Isotechnika Pharma Inc > Data driven
View:
Post by professional11 on Jun 25, 2010 4:33pm

Data driven

My investments are data driven.  I have held my position and plan to purchase more ISA in the near future.  As to the questions posted recently, I hope to collect my thoughts and send them out tonight...  clearly there is plenty to discuss.

P11
Comment by BornReady1970 on Jun 25, 2010 4:47pm
There are two types of data:Clinical - ISA has good clinical data. I don't think there is anyone on this board that has ever effectively shot holes in Volco, and most are very positive on the drug.Business - ISA has taken a very promising drug and managed to move it's share price from over $5.00 to .25. That is real data. ISA has publicaly disclosed that it has cash flow until Q4 of 2010 ...more  
Isotechnika Pharma Inc
The Market Update
{{currentVideo.title}} {{currentVideo.relativeTime}}
< Previous bulletin
Next bulletin >

At the Bell logo
A daily snapshot of everything
from market open to close.

{{currentVideo.companyName}}
{{currentVideo.intervieweeName}}{{currentVideo.intervieweeTitle}}
{{currentVideo.headline}}
{{currentVideo.link1Text}}
{{currentVideo.link2Text}}
< Previous
{{moreVideoText}}
Next >
Dealroom for high-potential pre-IPO opportunities